Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06740331
Recruiting Not applicable

Social Cognition, Memory, and Executive Functions in Bipolar Disorder and Major Depressive Disorder

NCT06740331 · tracked via the Priya Life Science France tracker
Sponsor
CHU de Reims
Phase
Not applicable
Started
2025-01-07
Last updated
2026-03-13

Condition(s) studied

Bipolar Disorder and Major Depressive Disorder

Investigational drug(s) / intervention(s)

Analysis of social cognition, memory functioning, and executive functioning processes

Analysis of social cognition, memory functioning, and executive functioning processes: Investigation of social cognition, memory functioning, and executive processes using a comprehensive clinical and cognitive assessment

Study summary

Bipolar disorder (BD) are common psychiatric disorders often misdiagnosed, leading to delayed treatment. Even during stable phases, individuals with bipolar disorder experience residual cognitive impairments that affect their social functioning and quality of life.

This study aims to explore social cognition deficits (e.g., emotional processing, theory of mind, attribution bias) and their relationship with executive functions (e.g., flexibility, inhibition, working memory) and memory in bipolar disorder and major depressive disorder, ultimately seeking to improve understanding of their functional outcomes.

Social cognition and executive functions in BD are both state- and trait-related. One recent meta-analysis demonstrated impairment in social cognitive domains for manic, depressive, and euthymic bipolar disorders' patients but it remains unclear whether these social cognitive deficits in BD are due to executive functions and/or other confounding effects.

Few studies have investigated the interdependency between these cognitive impairments in these two affective disorders while a better understanding of the link between executive functions and social cognition seems crucial in order to better characterize the nature of patients' deficits and thus their caring.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion criteria: * Patients between 18 and 65 years old, men or women * Having a diagnosis of bipolar disorder or depressive disorder * No substantial change in treatment for 2 weeks preceding study enrollment * Being a native French speaker * Patients enrolled in the national healthcare insurance program * Consenting to participate to the study Exclusion criteria: * The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence * A significant general medical illness, including neurological disorders or head trauma * A sensorial impairment uncorrected (visual and/or hearing) Group 3: First-degree relatives of bipolar patients Inclusion criteria: * Participants between 18 and 65 years old, men or women * Participants having at least one first-degree relative presenting an bipolar disorder (parents, children, siblings) * Being a native French speaker * Patients enrolled in the national healthcare insurance program * Consenting to participate to the study Exclusion criteria: * A diagnosis of schizophrenia or of bipolar disorder or of depressive disorder according to DSM-5 criteria * The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence * A significant general medical illness, including neurological disorders or head trauma * A sensorial impairment uncorrected (visual and/or hearing) Group 4, 5, 6: Healthy control participants Inclusion criteria: * Participants between 18 and 65 years old, men or women * Being a native French speaker * Patients enrolled in the national healthcare insurance program * Consenting to participate to the study Exclusion criteria: * A diagnosis of schizophrenia or of bipolar disorder or of major depressive disorder according to DSM-5 criteria * The presence of any alcohol use disorder or any other substance use disorder in the last six months, except for tobacco dependence * Participants having one first-degree relative presenting an bipolar disorder or depressive disorder or schizophrenia according to DSM-5 criteria * A significant general medical illness, including neurological disorders or head trauma * A sensorial impairment uncorrected (visual and/or hearing)

Primary outcome measure(s)

  • Social cognition: facial emotion recognition — Day 0
    Evaluated through Penn Emotion Recognition Task (Emotion Recognition, ER-40). The ER-40 asks participants to assign an emotion to 40 photographs depicting expressions of one of 5 emotions (happiness, sadness, anger, fear and neutral), 4 each of low and high intensity. Are measured the number of correct responses and type of errors.

Trial sites (1)

FacilityCityRegionStatus
Chu Reims Reims France Recruiting

More CHU de Reims trials in France

Difficult Intravenous Access in Pediatric Patients: Paramedical Care Using Ultrasound Guidance Recruiting
Sensory Stimulation Program Delivered by Family Members of Brain-injured Patients in Critical Care: Effect on Relatives' Post-traumatic Stress Starting soon
Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS) Recruiting
Intraoral Scanners as Periodontal and Dental Pathologies Diagnosis Tools Recruiting
Coding of Speech Signals in the Human Auditory Nerve Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06740331 on ClinicalTrials.gov ↗ ← All trials in France